175 related articles for article (PubMed ID: 10976550)
21. The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism.
Kortunay S; Basci NE; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
Eur J Clin Pharmacol; 1997; 53(3-4):261-4. PubMed ID: 9476042
[TBL] [Abstract][Full Text] [Related]
22. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
Brøsen K; de Morais SM; Meyer UA; Goldstein JA
Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
[TBL] [Abstract][Full Text] [Related]
23. Polymorphic oxidative metabolism of proguanil in a Nigerian population.
Bolaji OO; Sadare IO; Babalola CP; Ogunbona FA
Eur J Clin Pharmacol; 2002 Nov; 58(8):543-5. PubMed ID: 12451432
[TBL] [Abstract][Full Text] [Related]
24. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
25. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.
Laine K; Tybring G; Bertilsson L
Clin Pharmacol Ther; 2000 Aug; 68(2):151-9. PubMed ID: 10976546
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.
Xie HG; Kim RB; Stein CM; Wilkinson GR; Wood AJ
Br J Clin Pharmacol; 1999 Sep; 48(3):402-8. PubMed ID: 10510153
[TBL] [Abstract][Full Text] [Related]
27. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.
Kaneko A; Lum JK; Yaviong L; Takahashi N; Ishizaki T; Bertilsson L; Kobayakawa T; Björkman A
Pharmacogenetics; 1999 Oct; 9(5):581-90. PubMed ID: 10591538
[TBL] [Abstract][Full Text] [Related]
28. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
[TBL] [Abstract][Full Text] [Related]
29. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
[TBL] [Abstract][Full Text] [Related]
30. Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil.
Kaneko A; Bergqvist Y; Takechi M; Kalkoa M; Kaneko O; Kobayakawa T; Ishizaki T; Björkman A
J Infect Dis; 1999 Apr; 179(4):974-9. PubMed ID: 10068594
[TBL] [Abstract][Full Text] [Related]
31. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
[TBL] [Abstract][Full Text] [Related]
32. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu.
Kaneko A; Kaneko O; Taleo G; Björkman A; Kobayakawa T
Lancet; 1997 Mar; 349(9056):921-2. PubMed ID: 9093256
[No Abstract] [Full Text] [Related]
33. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
34. Influence of the genetic polymorphisms in the 5' flanking and exonic regions of CYP2C19 on proguanil oxidation.
Satyanarayana CR; Devendran A; Jayaraman M; Mannu J; Mathur PP; Gopal SD; Rajagopal K; Chandrasekaran A
Drug Metab Pharmacokinet; 2009; 24(6):537-48. PubMed ID: 20045989
[TBL] [Abstract][Full Text] [Related]
35. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
[TBL] [Abstract][Full Text] [Related]
36. The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides.
Wright JD; Helsby NA; Ward SA
Br J Clin Pharmacol; 1995 Apr; 39(4):441-4. PubMed ID: 7640152
[TBL] [Abstract][Full Text] [Related]
37. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
Furuta T; Ohashi K; Kosuge K; Zhao XJ; Takashima M; Kimura M; Nishimoto M; Hanai H; Kaneko E; Ishizaki T
Clin Pharmacol Ther; 1999 May; 65(5):552-61. PubMed ID: 10340921
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects.
Ieiri I; Kubota T; Urae A; Kimura M; Wada Y; Mamiya K; Yoshioka S; Irie S; Amamoto T; Nakamura K; Nakano S; Higuchi S
Clin Pharmacol Ther; 1996 Jun; 59(6):647-53. PubMed ID: 8681489
[TBL] [Abstract][Full Text] [Related]
39. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers.
Tamminga WJ; Wemer J; Oosterhuis B; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2001 Dec; 57(10):717-22. PubMed ID: 11829201
[TBL] [Abstract][Full Text] [Related]
40. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
Sagar M; Seensalu R; Tybring G; Dahl ML; Bertilsson L
Scand J Gastroenterol; 1998 Oct; 33(10):1034-8. PubMed ID: 9829356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
